Last 12 months
Inside the activity.
0 purchase rows · 20 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 7 |
| Mar 2026 | 0 | 3 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 1 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 5 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2023 Filed Feb 14, 2023 20:01 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Tax withholdingCommon Stock | 85 | $248.13 | $21,091.05 |
DisclosureSEC source: 0001127602-23-005105 · form4.xml · nonDerivative · entry 2 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,168 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 19:57 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Tax withholdingCommon Stock | 142 | $248.13 | $35,234.46 |
DisclosureSEC source: 0001127602-23-005103 · form4.xml · nonDerivative · entry 2 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,069 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 19:59 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Tax withholdingCommon Stock | 124 | $248.13 | $30,768.12 |
DisclosureSEC source: 0001127602-23-005104 · form4.xml · nonDerivative · entry 2 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,412.7624 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 19:56 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Tax withholdingCommon Stock | 195 | $248.13 | $48,385.35 |
DisclosureSEC source: 0001127602-23-005102 · form4.xml · nonDerivative · entry 2 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,640 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 19:55 UTC |
Schechter Adam HDirector · President & CEO
|
Tax withholdingCommon Stock | 1,170 | $248.13 | $290,312.10 |
DisclosureSEC source: 0001127602-23-005101 · form4.xml · nonDerivative · entry 2 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,181 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 19:54 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Tax withholdingCommon Stock | 114 | $248.13 | $28,286.82 |
DisclosureSEC source: 0001127602-23-005100 · form4.xml · nonDerivative · entry 2 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,996.4022 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 19:51 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
Tax withholdingCommon Stock | 54 | $248.13 | $13,399.02 |
DisclosureSEC source: 0001127602-23-005098 · form4.xml · nonDerivative · entry 2 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 703 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 19:52 UTC |
Seltz Judith CEVP, CHRO
|
Tax withholdingCommon Stock | 69 | $248.13 | $17,120.97 |
DisclosureSEC source: 0001127602-23-005099 · form4.xml · nonDerivative · entry 2 Seltz Judith C · CIK 0001791228 · EVP, CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,964.9485 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 19:50 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Tax withholdingCommon Stock | 78 | $248.13 | $19,354.14 |
DisclosureSEC source: 0001127602-23-005097 · form4.xml · nonDerivative · entry 2 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,552.7592 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 13, 2023 Filed Feb 14, 2023 19:49 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Tax withholdingCommon Stock | 38 | $248.13 | $9,428.94 |
DisclosureSEC source: 0001127602-23-005096 · form4.xml · nonDerivative · entry 2 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,160.2194 F2 · kind: Stock withholding to satisfy tax withholding obligations. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:25 UTC |
BELINGARD JEAN-LUCDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005114 · form4.xml · derivative · entry 3 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849 Underlying: Common Stock · 742 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units vested fully on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units vested fully on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:25 UTC |
BELINGARD JEAN-LUCDirector
|
Exercise / conversionCommon Stock | 742 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005114 · form4.xml · nonDerivative · entry 1 BELINGARD JEAN-LUC · CIK 0001200845 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:22 UTC |
ANDERSON KERRII BDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005113 · form4.xml · derivative · entry 4 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849 Underlying: Common Stock · 742 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 11, 2023. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:22 UTC |
ANDERSON KERRII BDirector
|
Exercise / conversionCommon Stock | 742 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005113 · form4.xml · nonDerivative · entry 1 ANDERSON KERRII B · CIK 0001227159 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,275 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:17 UTC |
Davis Jeffrey A.Director
|
Exercise / conversionRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005112 · form4.xml · derivative · entry 2 Davis Jeffrey A. · CIK 0001648477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849 Underlying: Common Stock · 742 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 11, 2023. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:17 UTC |
Davis Jeffrey A.Director
|
Exercise / conversionCommon Stock | 742 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005112 · form4.xml · nonDerivative · entry 1 Davis Jeffrey A. · CIK 0001648477 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,672 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:16 UTC |
Gilliland Dwight GaryDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005111 · form4.xml · derivative · entry 2 Gilliland Dwight Gary · CIK 0001603769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849 Underlying: Common Stock · 742 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 11, 2023. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:16 UTC |
Gilliland Dwight GaryDirector
|
Exercise / conversionCommon Stock | 742 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005111 · form4.xml · nonDerivative · entry 1 Gilliland Dwight Gary · CIK 0001603769 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:15 UTC |
Kong GarhengDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005110 · form4.xml · derivative · entry 2 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849 Underlying: Common Stock · 742 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 11, 2023. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:15 UTC |
Kong GarhengDirector
|
Exercise / conversionCommon Stock | 742 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005110 · form4.xml · nonDerivative · entry 1 Kong Garheng · CIK 0001435183 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,951 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:14 UTC |
NEUPERT PETER MDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005109 · form4.xml · derivative · entry 2 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849 Underlying: Common Stock · 742 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 11, 2023. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:14 UTC |
NEUPERT PETER MDirector
|
Exercise / conversionCommon Stock | 742 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005109 · form4.xml · nonDerivative · entry 1 NEUPERT PETER M · CIK 0001237566 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,996 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:13 UTC |
Parham Richelle PDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005108 · form4.xml · derivative · entry 2 Parham Richelle P · CIK 0001550078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849 Underlying: Common Stock · 742 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 11, 2023. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:13 UTC |
Parham Richelle PDirector
|
Exercise / conversionCommon Stock | 742 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005108 · form4.xml · nonDerivative · entry 1 Parham Richelle P · CIK 0001550078 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,587 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:11 UTC |
Wengel Kathryn EDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005107 · form4.xml · derivative · entry 2 Wengel Kathryn E · CIK 0001745955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849 Underlying: Common Stock · 742 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 11, 2023. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:11 UTC |
Wengel Kathryn EDirector
|
Exercise / conversionCommon Stock | 742 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005107 · form4.xml · nonDerivative · entry 1 Wengel Kathryn E · CIK 0001745955 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:07 UTC |
Williams R SandersDirector
|
Exercise / conversionRestricted Stock Unit · Derivative | 742 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005106 · form4.xml · derivative · entry 2 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 849 Underlying: Common Stock · 742 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vested fully on February 11, 2023. F2 · derivative.expiration_date: The Restricted Stock Units vested fully on February 11, 2023. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:07 UTC |
Williams R SandersDirector
|
Exercise / conversionCommon Stock | 742 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005106 · form4.xml · nonDerivative · entry 1 Williams R Sanders · CIK 0001375347 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,173 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:01 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Exercise / conversionRestricted Stock Unit · Derivative | 290 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005105 · form4.xml · derivative · entry 3 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,827 Underlying: Common Stock · 290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 20:01 UTC |
BERBERIAN LANCEEVP, CIO & CTO
|
Exercise / conversionCommon Stock | 290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005105 · form4.xml · nonDerivative · entry 1 BERBERIAN LANCE · CIK 0001102900 · EVP, CIO & CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,253 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:57 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionRestricted Stock Unit · Derivative | 483 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005103 · form4.xml · derivative · entry 3 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,001 Underlying: Common Stock · 483 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:57 UTC |
Kirchgraber Paul RCEO, Covance Drug Development
|
Exercise / conversionCommon Stock | 483 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005103 · form4.xml · nonDerivative · entry 1 Kirchgraber Paul R · CIK 0001791393 · CEO, Covance Drug Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,211 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:59 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionRestricted Stock Unit · Derivative | 423 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005104 · form4.xml · derivative · entry 3 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,681 Underlying: Common Stock · 423 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:59 UTC |
Caveney Brian JEVP, President of Diagnostics
|
Exercise / conversionCommon Stock | 423 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005104 · form4.xml · nonDerivative · entry 1 Caveney Brian J · CIK 0001717915 · EVP, President of Diagnostics 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,536.7624 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:56 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionRestricted Stock Unit · Derivative | 723 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005102 · form4.xml · derivative · entry 3 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,764 Underlying: Common Stock · 723 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:56 UTC |
EISENBERG GLENN AChief Financial Officer, EVP
|
Exercise / conversionCommon Stock | 723 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005102 · form4.xml · nonDerivative · entry 1 EISENBERG GLENN A · CIK 0001222831 · Chief Financial Officer, EVP 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,835 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:55 UTC |
Schechter Adam HDirector · President & CEO
|
Exercise / conversionRestricted Stock Unit · Derivative | 2,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005101 · form4.xml · derivative · entry 3 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,828 Underlying: Common Stock · 2,656 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:55 UTC |
Schechter Adam HDirector · President & CEO
|
Exercise / conversionCommon Stock | 2,656 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005101 · form4.xml · nonDerivative · entry 1 Schechter Adam H · CIK 0001376841 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,351 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:54 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionRestricted Stock Unit · Derivative | 423 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005100 · form4.xml · derivative · entry 3 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,681 Underlying: Common Stock · 423 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:54 UTC |
Schroeder Mark SEVP, President-Diagnostics Lab
|
Exercise / conversionCommon Stock | 423 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005100 · form4.xml · nonDerivative · entry 1 Schroeder Mark S · CIK 0001793112 · EVP, President-Diagnostics Lab 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,110.4022 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:51 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 180 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005098 · form4.xml · derivative · entry 3 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,520 Underlying: Common Stock · 180 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:51 UTC |
Summy Amy B.EVP, Chief Marketing Officer
|
Exercise / conversionCommon Stock | 180 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005098 · form4.xml · nonDerivative · entry 1 Summy Amy B. · CIK 0001805303 · EVP, Chief Marketing Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 757 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:52 UTC |
Seltz Judith CEVP, CHRO
|
Exercise / conversionRestricted Stock Unit · Derivative | 236 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005099 · form4.xml · derivative · entry 3 Seltz Judith C · CIK 0001791228 · EVP, CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,464 Underlying: Common Stock · 236 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:52 UTC |
Seltz Judith CEVP, CHRO
|
Exercise / conversionCommon Stock | 236 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005099 · form4.xml · nonDerivative · entry 1 Seltz Judith C · CIK 0001791228 · EVP, CHRO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,033.9485 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:50 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 290 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005097 · form4.xml · derivative · entry 3 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,767 Underlying: Common Stock · 290 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:50 UTC |
van der Vaart Sandra DEVP, Chief Legal Officer
|
Exercise / conversionCommon Stock | 290 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005097 · form4.xml · nonDerivative · entry 1 van der Vaart Sandra D · CIK 0001537208 · EVP, Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,630.7592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:49 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionRestricted Stock Unit · Derivative | 110 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-005096 · form4.xml · derivative · entry 3 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 747 Underlying: Common Stock · 110 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F3 · derivative.exercise_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F3 · derivative.expiration_date: The Restricted Stock Units that have vested were part of a grant that vests in three equal annual installments beginning on February 11, 2023. F4 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
| February 11, 2023 Filed Feb 14, 2023 19:49 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
Exercise / conversionCommon Stock | 110 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001127602-23-005096 · form4.xml · nonDerivative · entry 1 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,198.2194 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 17:43 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
GrantNon-qualified Stock Options · Derivative | 1,100 | $0.00 Strike: $247.24 | $0.00 |
DisclosureSEC source: 0001127602-23-004136 · form4.xml · derivative · entry 2 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 Underlying: Common Stock · 1,100 shares Expires 2033-02-06 F4 · security: Employee stock option (right to buy) granted pursuant to the Laboratory Corporation of America Holdings 2016 Omnibus Incentive Plan. F5 · derivative.exercise_date: The option vests in three equal annual installments beginning on the date reflected in this column. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 17:43 UTC |
Wilkinson Peter JSVP, Chief Accounting Officer
|
GrantRestricted Stock Unit · Derivative | 360 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-004136 · form4.xml · derivative · entry 1 Wilkinson Peter J · CIK 0001398138 · SVP, Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 857 Underlying: Common Stock · 360 shares Expires not disclosed F1 · derivative.exercise_price: Each Restricted Stock Unit represents the contingent right to receive one share of Laboratory Corporation of America Holdings Common Stock. F2 · derivative.exercise_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F2 · derivative.expiration_date: The Restricted Stock Units vest in three equal annual installments beginning on February 7, 2024. F3 · balance_after: This number reflects the aggregate number of Restricted Stock Units held by the reporting person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.